Smith & Nephew (NYSE:SNN – Get Free Report) was downgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, MarketBeat.com reports.
Separately, StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Smith & Nephew presently has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Report on SNN
Smith & Nephew Trading Up 0.6 %
Institutional Trading of Smith & Nephew
A number of large investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC lifted its holdings in Smith & Nephew by 13.8% in the 1st quarter. Janney Montgomery Scott LLC now owns 9,611 shares of the medical equipment provider’s stock valued at $244,000 after purchasing an additional 1,165 shares in the last quarter. Inspire Advisors LLC lifted its stake in shares of Smith & Nephew by 4.7% during the first quarter. Inspire Advisors LLC now owns 21,647 shares of the medical equipment provider’s stock valued at $549,000 after buying an additional 970 shares during the period. Headlands Technologies LLC boosted its position in Smith & Nephew by 225.0% during the first quarter. Headlands Technologies LLC now owns 3,851 shares of the medical equipment provider’s stock worth $98,000 after acquiring an additional 2,666 shares during the last quarter. QRG Capital Management Inc. grew its stake in Smith & Nephew by 47.0% in the 1st quarter. QRG Capital Management Inc. now owns 93,034 shares of the medical equipment provider’s stock worth $2,359,000 after acquiring an additional 29,754 shares during the period. Finally, Henry James International Management Inc. raised its holdings in Smith & Nephew by 12.2% in the 1st quarter. Henry James International Management Inc. now owns 205,417 shares of the medical equipment provider’s stock valued at $5,209,000 after acquiring an additional 22,341 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
- Five stocks we like better than Smith & Nephew
- 3 REITs to Buy and Hold for the Long Term
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- What is Put Option Volume?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- What is the Dow Jones Industrial Average (DJIA)?
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.